PE20240145A1 - Alfa-1-antitripsina (aat) en el tratamiento y/o prevencion de trastornos neurologicos - Google Patents
Alfa-1-antitripsina (aat) en el tratamiento y/o prevencion de trastornos neurologicosInfo
- Publication number
- PE20240145A1 PE20240145A1 PE2023002991A PE2023002991A PE20240145A1 PE 20240145 A1 PE20240145 A1 PE 20240145A1 PE 2023002991 A PE2023002991 A PE 2023002991A PE 2023002991 A PE2023002991 A PE 2023002991A PE 20240145 A1 PE20240145 A1 PE 20240145A1
- Authority
- PE
- Peru
- Prior art keywords
- aat
- disease
- prevention
- treatment
- antytripsin
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 abstract 3
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 abstract 3
- 229940024142 alpha 1-antitrypsin Drugs 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 150000007523 nucleic acids Chemical group 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invencion se refiere a una composicion que comprende una proteina alfa1-antitripsina (AAT), una variante, una isoforma y/o un fragmento de esta para su uso en el tratamiento y/o prevencion de una enfermedad o trastorno de! sistema nervioso o un sintoma de este, seleccionado del grupo de demencia, esclerosis multiple, esclerosis lateral amiotrofica, enfermedad de Alzheimer, enfermedad de Parkinson y enfermedad de Huntington. Tambien se refiere a un vector que comprende una secuencia de acidos nucleicos que codifica una proteina AAT y a una celula modificada geneticamente.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2021/061597 WO2021219896A1 (en) | 2020-05-01 | 2021-05-03 | Treatment and/or prevention of a disease or a syndrome related to a virus infection |
| EP21206096 | 2021-11-02 | ||
| EP22168622 | 2022-04-14 | ||
| PCT/EP2022/061882 WO2022189679A1 (en) | 2021-05-03 | 2022-05-03 | Alpha-1-antitrypsin (aat) in the treatment and/or prevention of neurological disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240145A1 true PE20240145A1 (es) | 2024-02-01 |
Family
ID=81392740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002991A PE20240145A1 (es) | 2021-05-03 | 2022-05-03 | Alfa-1-antitripsina (aat) en el tratamiento y/o prevencion de trastornos neurologicos |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4333875A1 (es) |
| JP (1) | JP2024517834A (es) |
| KR (1) | KR20240004531A (es) |
| AU (1) | AU2022233960A1 (es) |
| BR (1) | BR112023022486A2 (es) |
| CA (1) | CA3213739A1 (es) |
| CL (1) | CL2023003169A1 (es) |
| IL (1) | IL307433A (es) |
| PE (1) | PE20240145A1 (es) |
| WO (1) | WO2022189679A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117590006B (zh) * | 2024-01-19 | 2024-03-29 | 天津医科大学眼科医院 | 生物标志物在制备诊断Vogt-小柳原田综合征的产品中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017312113B2 (en) * | 2016-08-17 | 2023-05-25 | Factor Bioscience Inc. | Nucleic acid products and methods of administration thereof |
-
2022
- 2022-05-03 EP EP22719600.3A patent/EP4333875A1/en active Pending
- 2022-05-03 JP JP2023568050A patent/JP2024517834A/ja active Pending
- 2022-05-03 IL IL307433A patent/IL307433A/en unknown
- 2022-05-03 CA CA3213739A patent/CA3213739A1/en active Pending
- 2022-05-03 PE PE2023002991A patent/PE20240145A1/es unknown
- 2022-05-03 KR KR1020237039503A patent/KR20240004531A/ko unknown
- 2022-05-03 AU AU2022233960A patent/AU2022233960A1/en active Pending
- 2022-05-03 WO PCT/EP2022/061882 patent/WO2022189679A1/en active Application Filing
- 2022-05-03 BR BR112023022486A patent/BR112023022486A2/pt unknown
-
2023
- 2023-10-24 CL CL2023003169A patent/CL2023003169A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3213739A1 (en) | 2022-09-15 |
| BR112023022486A2 (pt) | 2024-01-16 |
| EP4333875A1 (en) | 2024-03-13 |
| KR20240004531A (ko) | 2024-01-11 |
| CL2023003169A1 (es) | 2024-04-12 |
| JP2024517834A (ja) | 2024-04-23 |
| AU2022233960A1 (en) | 2023-10-05 |
| IL307433A (en) | 2023-12-01 |
| WO2022189679A1 (en) | 2022-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018012096A2 (es) | Proteínas de fusión gdf15 y usos de estas | |
| MX2022004102A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| SA519400950B1 (ar) | Masp-3 تركيبات وطرق لتثبيط لعلاج أمراض واضطرابات مختلفة | |
| MA43335B1 (fr) | Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr | |
| EA202090871A1 (ru) | Ингибирование убиквитин-специфической пептидазы 30 | |
| MX2023009652A (es) | Inhibidores peptidicos de la acumulacion de alfa-sinucleina basados en estructuras. | |
| WO2019075456A3 (en) | Methods and substances for prevention and treatment of neurodegenerative diseases | |
| PE20240145A1 (es) | Alfa-1-antitripsina (aat) en el tratamiento y/o prevencion de trastornos neurologicos | |
| MX2023001877A (es) | Meganucleasas dise?adas especificas para secuencias de reconocimiento en el gen pcsk9. | |
| AR119389A1 (es) | Inhibidores de péptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias | |
| ECSP20042640A (es) | Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer | |
| CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
| BR112021022067A2 (pt) | Inibidores de kcnt1 e métodos de uso | |
| BR112022012230A2 (pt) | Variantes de progranulina | |
| GT200500070A (es) | Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos | |
| BR112021021912A2 (pt) | Nova nuclease omni-50 crispr | |
| MX2019006495A (es) | Tratamiento de enfermedades neurologicas. | |
| EA202092557A1 (ru) | СОЕДИНЕНИЯ ТЕТРАГИДРОБЕНЗОФУРО[2,3-c]ПИРИДИНА И БЕТА-КАРБОЛИНА ДЛЯ ЛЕЧЕНИЯ, ОБЛЕГЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАССТРОЙСТВ, СВЯЗАННЫХ С АГРЕГАТАМИ ТАУ-БЕЛКА | |
| MX2019002321A (es) | Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas. | |
| BR112017011226A2 (pt) | peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica | |
| CO2022002627A2 (es) | Composiciones biofarmacéuticas y procedimientos conexos | |
| MX2019003087A (es) | Inhibidores cetónicos de gingipain de lisina. | |
| PH12021550213A1 (en) | Methods for treating neurodegenerative disorders | |
| BR112022003025A2 (pt) | Moléculas que se ligam a tdp-43 para o tratamento de esclerose lateral amiotrófica e distúrbios relacionados | |
| MX2016003878A (es) | Composicion, proceso de produccion y uso de composicion para tratamiento de desordenes del sistema nervioso central. |